TXG · 10x Genomics, Inc.
$63.87
+1.68 (+2.70%)
At close · Aug 20
Market Cap
$8.32B
Shares
130.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$63.87
Open$60.70
Day$60.69–64.53
52W close$11.34–63.87
Avg vol 30d3.1M
Short int15.6M · 12.0% float · 5.8d
Short vol66%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+143%
above
Price vs 50-day avg
+45%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
100%
near high
Momentum
relative strength
1-month return
+33%
trailing
6-month return
+177%
trailing
YTD return
+292%
this year
Relative strength
+166%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $44 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +99 funds added
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Falling
11.99% of float · ▼ -3.9% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
388 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+68%
Y/Y
Gross margin
181%
contracting
EPS growth
+77%
Y/Y
Free cash flow
$130.1M
Balance sheet
$344.1M
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue
· full year 2026
Initiated
$610M – $630M
prior FY $642.82M
midpoint −3.6% Y/Y
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Revenue
· fourth quarter 2025
$154M – $158M
Guided vs delivered
· last 4 settled
Revenue
fourth quarter 2025
guided $154M – $158M
$166.03M
Beat +6.4%
Revenue
third quarter 2025
guided $140M – $144M
$149M
Beat +4.9%
Full-year revenue
full year 2024
guided $670M – $690M
$610.79M
Miss −10.2%
Full year revenue
full year 2023
guided $610M – $625M
$618.73M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+143%
Bullish
Price vs 50-day avg
+45%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $44 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +99 funds added
Insider flow
Distributing
Net -$1.2M over 90 days · 100% sells
Short interest
Falling
11.99% of float · ▼ -3.9% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
388 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $64 · 100%
Range high $64
vs 200-day avg +143%
vs 50-day avg +45%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cumulative Chromium instruments sold | 6,400 | full year 2025 | — |
| Cumulative Spatial instruments sold | 1,500 | full year 2025 | — |
| Single Cell consumables reactions sold growth | 20% | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXG
this stock
10x Genomics, Inc.
|
$8.32B | +291.6% | +68.1% | — | 12.0% |
|
VEEV
Veeva Systems Inc
|
$40.70B | +12.2% | +28.1% | 44.4 | 4.5% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.02B | -24.9% | — | — | 0.0% |
|
TEM
Tempus AI, Inc.
|
$11.98B | +12.9% | +83.4% | — | 18.4% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.78B | +59.0% | +28.2% | 36.1 | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXG | +9.8% | +32.9% | +177.1% | +35.1% | +291.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +11.8% | +29.6% | +165.9% | +33.0% | +279.8% |
Key facts
CIK
1770787
CUSIP
88025U109
13F (30d)
357 filings
348 filers
Visit website
Investor relations